JP2006508958A5 - - Google Patents

Claims (27)

Peripheral neuropathy induced anticancer proviso that the anticancer agent is not taxol or cisplatin, for the prevention and / or treatment of peripheral neuropathy induced by administration of acetyl L- carnitine or a pharmaceutically acceptable salt thereof A pharmaceutical composition containing. 2. A pharmaceutical composition according to claim 1 wherein the medicament is suitable for administration in a coordinated manner. Or 2. The pharmaceutical composition according to 2 . The medicament according to claim 3, wherein the anticancer agent is selected from the group consisting of carboplatin, oxaliplatin, docetaxel, epothilone, vinorelbine, vincristine, farnesyltransferase inhibitor R11577, thalidomide, cryptophysin analog LY355703, and proteasome inhibitor PS341. Composition . The pharmaceutical composition according to any of claims 2 to 4, wherein the administration is substantially simultaneous. The pharmaceutical composition according to any of claims 2 to 4, wherein the administration is sequential. The administration is in the form of a composition comprising a combination of the acetyl L-carnitine or a pharmaceutically acceptable salt thereof in combination with an anti-cancer agent, and optionally a pharmaceutically acceptable excipient and / or vehicle. The pharmaceutical composition according to any one of claims 2 to 5. The pharmaceutical composition according to any of claims 1 to 7, wherein 0.1 to 3 g / day of acetyl L-carnitine or an equivalent amount of a pharmaceutically acceptable salt thereof is administered. The pharmacologically acceptable salts of acetyl L-carnitine are chloride, bromide, orotate, acid aspartate, acid citrate, acid phosphate, fumaric acid and acid fumaric acid, maleate And a pharmaceutical composition according to any of claims 1 to 8, selected from the group consisting of acid maleic acid, acid oxalate, acid sulfate, glucose phosphate, tartrate and acid tartrate. The pharmaceutical composition according to any one of claims 1 to 4 and 6 to 9, wherein the medicament is administered to a subject who is considered to require treatment with the anticancer agent. The pharmaceutical composition according to claim 10, wherein the pharmaceutical is administered immediately before or after the surgical removal of the tumor. 11. The pharmaceutical composition according to claim 10, wherein the anticancer agent is an alternative to surgical removal of the tumor. The pharmaceutical composition according to any one of claims 1 to 12, wherein another carnitine or a pharmaceutically acceptable salt thereof is added. The pharmaceutical composition according to any one of claims 1 to 13, wherein an additional anticancer agent is added. a) Acetyl L-carnitine or a pharmaceutically acceptable salt thereof,
b) A composition comprising a combination of peripheral neuropathy-inducing anticancer agents. 16. The composition of claim 15, wherein the anticancer agent is selected from the group of platin compound families, taxanes, epothilones, vinca alkaloids. The composition according to claim 16, wherein the anticancer agent is selected from the group consisting of a platin compound, a taxane, an epothilone and a vinca alkaloid, a farnesyltransferase inhibitor, a thalidomide, 5-fluorouracil, a cryptophysin analog, and a proteasome inhibitor. . The composition according to claim 17, wherein the anticancer agent is selected from the group consisting of carboplatin, oxaliplatin, docetaxel, epothilone, vinorelbine, vincristine, farnesyltransferase inhibitor R11577, thalidomide, cryptophysin analog LY355703, and proteasome inhibitor PS341. object. The pharmacologically acceptable salts of acetyl L-carnitine are chloride, bromide, orotate, acid aspartate, acid citrate, acid phosphate, fumarate and acid fumarate, maleic acid 19. A composition according to any of claims 15-18, selected from the group consisting of salts and acid maleates, acid oxalates, acid sulfates, glucose phosphates, tartrate and acid tartrate. 20. A composition according to any of claims 15 to 19, wherein another carnitine or a pharmaceutically acceptable salt thereof is added. 21. A composition according to any of claims 15-20, wherein another anticancer agent is added. a) a pharmaceutical composition comprising a therapeutically effective amount of a peripheral neuropathy-inducing anticancer agent;
b) comprising a pharmaceutical composition comprising acetyl L-carnitine or a pharmaceutically acceptable salt thereof in an amount suitable to produce a substantial protective effect against peripheral neuropathy induced by administration of said anticancer agent. ,
kit. The kit according to claim 22, wherein the anticancer agent is selected from the group of platin compounds, taxanes, epothilones and vinca alkaloids, farnesyltransferase inhibitors, thalidomide, 5-fluorouracil, cryptophysin analogs, proteasome inhibitors. The kit according to claim 23, wherein the anticancer agent is selected from the group consisting of carboplatin, oxaliplatin, docetaxel, epothilone, vinorelbine, vincristine, farnesyltransferase inhibitor R11577, thalidomide, cryptophysin analog LY355703, and proteasome inhibitor PS341. . Pharmacologically acceptable salts of acetyl L-carnitine are chloride, bromide, orotate, acid aspartate, acid citrate, acid phosphate, fumarate and acid fumarate, maleic acid 25. Kit according to any of claims 22 to 24, selected from the group consisting of salts and acid maleic acid, acid oxalate, acid sulfate, glucose phosphate, tartrate and acid tartrate. 26. Kit according to any of claims 22 to 25, wherein additional carnitine or a pharmaceutically acceptable salt thereof is added. 27. A composition according to any of claims 22 to 26, wherein an additional anticancer agent is added.